Fiducial Markers Market by Product (Metal Based Markers (Gold, Gold Combination) Polymer Markers), Cancer Type (Prostate, Lung, Breast), Modality (CT, CBCT, MRI, Ultrasound), End user (Hospitals, Outpatient Facilities) - Global Forecast to 2025

フィデューシャルマーカーの世界市場予測:製品別(金属ベースマーカー(金、金の組み合わせ)、ポリマーマーカー)、がん種類別(前立腺、肺、乳房)、モダリティ別(CT、CBCT、MRI、超音波)、エンドユーザー別(病院、外来施設)

◆タイトル:Fiducial Markers Market by Product (Metal Based Markers (Gold, Gold Combination) Polymer Markers), Cancer Type (Prostate, Lung, Breast), Modality (CT, CBCT, MRI, Ultrasound), End user (Hospitals, Outpatient Facilities) - Global Forecast to 2025
◆商品コード:MD 7554
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年2月21日
◆ページ数:147
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥604,550見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥711,550見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥872,050見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社はフィデューシャルマーカーの世界市場が、2019年95百万ドルから2025年123百万ドルまで、年平均4.5%成長すると予測しています。本調査レポートでは、フィデューシャルマーカーの世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場動向、製品別(金属ベースマーカー(金、金の組み合わせ)、ポリマーマーカー、その他)分析、モダリティ別(CT、CBCT、MRI、超音波)分析、がん種類別(前立腺、肺、乳房)分析、エンドユーザー別(病院、外来施設)分析、地域別分析、競争状況、企業概要などを含め、次の構成でお届け致します。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場動向
・フィデューシャルマーカーの世界市場:製品別(金属ベースマーカー(金、金の組み合わせ)、ポリマーマーカー、その他)
・フィデューシャルマーカーの世界市場:モダリティ別(CT、CBCT、MRI、超音波)
・フィデューシャルマーカーの世界市場:がん種類別(前立腺、肺、乳房)
・フィデューシャルマーカーの世界市場:エンドユーザー別(病院、外来施設)
・フィデューシャルマーカーの世界市場:地域別
・競争状況
・企業概要

“The fiducial markers market is projected to grow at a CAGR of 4.5% from 2019 to 2025.”
The global fiducial markers market is valued at USD 95 million in 2019 and expected to reach USD 123 million by 2025, at a CAGR of 4.5% from 2019 to 2025. The growth of the fiducial markers market is mainly attributed to factors such as the growing incidences of cancer, growing adoption of radiotherapy procedures, improving reimbursement scenario, and rising awareness on radiotherapy. These factors have prompted market players to improve and strengthen their current manufacturing and distribution capabilities—especially in emerging markets, which are expected to witness the highest growth. However, a dearth of skilled professionals, high marker costs, and a lack of adequate healthcare infrastructure are expected to limit market growth during the forecast period.

“The metal-based markers segment commanded the largest share of the fiducial markers market in 2018.”
Based on the product, the fiducial markers market is segmented into metal-based, polymer-based, and other fiducial markers. The metal-based markers segment is further subsegmented into pure gold markers, gold combination markers, and other metal-based markers (tungsten, platinum, and nitinol, among others). The metal-based markers segment commanded the largest share of the fiducial markers market in 2018. The growing adoption of IGRT for the treatment of prostate cancer and the rising incidences of prostate cancer are expected to fuel the adoption of metal-based fiducial markers in the near future.

“The CT/CBCT segment held the major share of the global market in 2018.”
In terms of modality, the fiducial markers market is classified into CT/CBCT, MRI, ultrasound, and radiotherapy. The CT/CBCT segment held the major share of the global market in 2018. It is anticipated to reach USD 54.0 million by 2025. CBCT is preferred for prostate and lung cancer indications, as it can effectively detect changes in the position of cancer tumors. This is supporting the growth of the CT/CBCT segment.

“North America is projected to hold the largest share of the market.”
The fiducial markers market, by region, is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. North America is projected to hold the largest share of the market, by region, during the forecast period. This is attributed to the expansion of the target patient population, favorable reimbursement scenario, greater accessibility to radiotherapy procedures, and the presence of major players in this region.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–45%, Tier 2–34%, and Tier 3– 21%
• By Designation: C-level–47%, Director-level–33%, and Others–20%
• By Region: North America–35%, Europe–32%, Asia Pacific–25%, Latin America–6%, and the Middle East & Africa–2%

In 2018, the global fiducial markers market was dominated by CIVCO Radiotherapy (US), IZI Medical Products (US), Boston Scientific Corporation (US), Naslund Medical AB (Sweden), and IBA (Belgium).

Research Coverage:
The report analyzes the market for various fiducial markers and their adoption patterns. It aims at estimating the market size and future growth potential of the fiducial markers market and its subsegments. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios offered by top players in the fiducial markers market
• Product Development/Innovation: Detailed insights on upcoming trends, R&D activities, and product launches in the fiducial markers market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the fiducial markers market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of leading market players.

【レポートの目次】

1 Introduction (Page No. – 15)
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Limitations
1.5 Stakeholders

2 Research Methodology (Page No. – 18)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Breakdown of Primaries
2.1.2.2 Key Data From Primary Sources
2.2 Market Size Estimation
2.2.1 Product-Based Market Estimation
2.2.2 End User-Based Market Size Estimation
2.2.3 Primary Research Validation
2.3 Market Breakdown & Data Triangulation
2.4 Assumptions for the Study
2.5 Research Limitations

3 Executive Summary (Page No. – 28)

4 Premium Insights (Page No. – 32)
4.1 Fiducial Markers: Market Overview
4.2 Fiducial Markers Market, By Product & Region, 2019
4.3 Market, By Modality, 2019–2025
4.4 Market, By Cancer Type, 2019 Vs. 2025
4.5 Market Share, By End User, 2019 Vs. 2025
4.6 Geographic Snapshot of the Market, 2019

5 Market Overview (Page No. – 37)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Incidence of Cancer
5.2.1.2 Improving Reimbursement Scenario
5.2.1.3 Rising Awareness on Radiotherapy
5.2.1.4 Rising Investments and Funding for Cancer Research
5.2.2 Restraints
5.2.2.1 Lack of Adequate Healthcare Infrastructure and Premium Pricing of Modalities
5.2.2.2 Alternative Therapies and High Marker Costs
5.2.3 Opportunities
5.2.3.1 Emerging Economies
5.2.4 Challenges
5.2.4.1 Complications Associated With the Placement of Fiducial Markers
5.2.4.2 Shortage of Trained Personnel

6 Market, By Product (Page No. – 43)
6.1 Introduction
6.2 Metal-Based Markers
6.2.1 Pure Gold Markers
6.2.1.1 Pure Gold Markers Hold the Largest Share of the Metal-Based Market
6.2.2 Gold Combination Markers
6.2.2.1 High-Precision Advantages and Versatility are Driving Demand for Gold Combination Markers
6.2.3 Other Metal-Based Markers
6.3 Polymer-Based Markers
6.3.1 Visibility Limitations Have Affected Demand for Polymer-Based Markers
6.4 Other Fiducial Markers

7 Market, By Modality (Page No. – 55)
7.1 Introduction
7.2 Ct/Cbct
7.2.1 Technological Advancements and Rising Adoption of Cbct are Expected to Fuel Market Growth
7.3 Ultrasound
7.3.1 Rising Preference for Minimally Invasive Procedures is Driving Demand for Ultrasound
7.4 MRI
7.4.1 High Adoption of Combined Ct-Mri Modalities for Fm Localization Will Drive Segmental Growth
7.5 Radiotherapy
7.5.1 High Success Rate of Sbrt Using Radiotherapy Systems Will Drive the Segment Growth

8 Market, By Cancer Type (Page No. – 61)
8.1 Introduction
8.2 Prostate Cancer
8.2.1 Prostate Cancer Holds the Largest Share of the Market, By Cancer Type
8.3 Lung Cancer
8.3.1 Technological Advancements and Product Approvals Will Drive Market Growth
8.4 Gastric Cancer
8.4.1 High Incidence of Gastric Cancer and Advancements in Treatment Support Market Growth
8.5 Breast Cancer
8.5.1 EffiCACy of Advanced Radiology Treatment for Breast Cancer Will Ensure the Growth of the Market
8.6 Other Cancers

9 Market, By End User (Page No. – 69)
9.1 Introduction
9.2 Hospitals & Outpatient Facilities
9.2.1 Hospitals & Outpatient Facilities Hold the Largest Share of the Market
9.3 Independent Radiotherapy Centers
9.3.1 Unfavorable Reimbursement Scenario Will Hamper Growth
9.4 Cancer Research Centers
9.4.1 Rising Investments and Funding Will Increase Research Activities and Support Market Growth

10 Market, By Region (Page No. – 74)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.1.1 US Commanded the Largest Share of the Market in 2018
10.2.2 Canada
10.2.2.1 Public-Private Initiatives are Expected to Support the Adoption of Radiotherapy Procedures and Fiducial Markers
10.3 Europe
10.3.1 Germany
10.3.1.1 Favorable Reimbursement Scenario for Radiotherapy is Supporting Market Growth in Germany
10.3.2 UK
10.3.2.1 Rising Cancer Incidence and the Presence of Highly Developed Healthcare Infrastructure are Supporting Market Growth in the UK
10.3.3 France
10.3.3.1 Increasing Access to Radiotherapy Will Drive Market Growth
10.3.4 Spain
10.3.4.1 Shortage of Human Resources and Lack of Accessibility May Hinder Market Growth
10.3.5 Italy
10.3.5.1 Rising Research Activities Will Support Market Growth
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.1.1 Japan Dominates the APAC Market
10.4.2 China
10.4.2.1 China Will Register the Highest Growth in the APAC Market Due to the Growing Target Patient Population
10.4.3 India
10.4.3.1 Indian Market is Expected to be Driven By the Surge in Patient Population and Favorable Government Initiatives
10.4.4 South Korea
10.4.4.1 Growing Adoption of Advanced EBRT is Contributing to Market Growth in the Country
10.4.5 Australia
10.4.5.1 Favorable Reimbursement Scenario Will Support Market Growth
10.4.6 Rest of APAC
10.5 Latin America
10.5.1 Brazil
10.5.1.1 Brazil Held the Largest Share of the Latin American Market in 2018
10.5.2 Mexico
10.5.2.1 Initiatives are Being Undertaken to Spread Awareness and Boost Access to Radiotherapy
10.5.3 Rest of Latam
10.6 Middle East & Africa
10.6.1 Poor Healthcare Infrastructure and Reimbursement Scenario Restrain Market Growth

11 Competitive Landscape (Page No. – 108)
11.1 Overview
11.2 Market Share Analysis
11.3 Competitive Scenario
11.3.1 Key Product Launches and Enhancements
11.3.2 Key Agreements, Partnerships, and Collaborations
11.3.3 Key Acquisitions
11.3.4 Key Expansions
11.4 Competitive Leadership Mapping
11.4.1 Visionary Leaders
11.4.2 Innovators
11.4.3 Dynamic Differentiators
11.4.4 Emerging Companies

12 Company Profiles (Page No. – 114)
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 CIVCO Radiotherapy
12.2 Boston Scientific Corporation
12.3 IZI Medical Products
12.4 IBA
12.5 Naslund Medical AB
12.6 Medtronic
12.7 Best Medical International, Inc.
12.8 Nanovi A/S
12.9 Carbon Medical Technologies
12.10 Eckert & Ziegler
12.11 Innovative Oncology Solutions
12.12 QlRad Inc.
12.13 Stellar Medical
12.14 JJ-Medtech
12.15 QFIX
12.16 Other Companies
12.16.1 Varian Medical Systems, Inc.
12.16.2 Beekley Corporation
12.16.3 Innomedicus Ag
12.16.4 Meditronix Corporation
12.16.5 Seedos Ltd

*Business Overview, Products Offered, Recent Developments, MnM View Might Not be Captured in Case of Unlisted Companies.

13 Appendix (Page No. – 138)
13.1 Discussion Guide
13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.3 Available Customizations
13.4 Related Reports
13.5 Author Details

List of Tables (113 Tables)

Table 1 National Average Medicare Reimbursement: Outpatient Prospective Payment System (Opps) Estimated Per Course
Table 2 Reimbursement for IMRT in Germany, 2017
Table 3 Market, By Product, 2017–2025 (USD Million)
Table 4 Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 5 Market, By Region, 2017–2025 (USD Million)
Table 6 Market, By Modality, 2017–2025 (USD Million)
Table 7 Market, By Cancer Type, 2017–2025 (USD Million)
Table 8 Market, By End User, 2017–2025 (USD Million)
Table 9 Pure Gold Fiducial Markers Market, By Region, 2017–2025 (USD Million)
Table 10 Market, By Modality, 2017–2025 (USD Million)
Table 11 Market, By Cancer Type, 2017–2025 (USD Million)
Table 12 Market, By End User, 2017–2025 (USD Million)
Table 13 Gold Combination Fiducial Markers Market, By Region, 2017–2025 (USD Million)
Table 14 Market, By Modality, 2017–2025 (USD Million)
Table 15 Market, By Cancer Type, 2017–2025 (USD Million)
Table 16 Market, By End User, 2017–2025 (USD Million)
Table 17 Other Metal-Based Fiducial Markers Market, By Region, 2017–2025 (USD Million)
Table 18 Market, By Modality, 2017–2025 (USD Million)
Table 19 Market, By Cancer Type, 2017–2025 (USD Million)
Table 20 Market, By End User, 2017–2025 (USD Million)
Table 21 Polymer-Based Fiducial Markers Market, By Region, 2017–2025 (USD Million)
Table 22 Market, By Modality, 2017–2025 (USD Million)
Table 23 Market, By Cancer Type, 2017–2025 (USD Million)
Table 24 Market, By End User, 2017–2025 (USD Million)
Table 25 Other Fiducial Markers Market, By Region, 2017–2025 (USD Million)
Table 26 Market, By Modality, 2017–2025 (USD Million)
Table 27 Market, By Cancer Type, 2017–2025 (USD Million)
Table 28 Market, By End User, 2017–2025 (USD Million)
Table 29 Market, By Modality, 2017–2025 (USD Million)
Table 30 Market for CT/CBCT, By Region, 2017–2025 (USD Million)
Table 31 Market for Ultrasound, By Region, 2017–2025 (USD Million)
Table 32 Market for Cancer Research Centers, By Region, 2017–2025 (USD Million)
Table 33 Conventional EBRT vs SBRT
Table 34 Market for Radiotherapy, By Region, 2017–2025 (USD Million)
Table 35 Market, By Cancer Type, 2017–2025 (USD Million)
Table 36 Newly Diagnosed Prostate Cancer Cases, By Key Country, 2018
Table 37 Market for Prostate Cancer, By Region, 2017–2025 (USD Million)
Table 38 Market for Lung Cancer, By Region, 2017–2025 (USD Million)
Table 39 New Gastric Cancer Cases Diagnosed, By Country, 2018
Table 40 Market for Gastric Cancer, By Region, 2017–2025 (USD Million)
Table 41 New Breast Cancer Cases Diagnosed, By Country, 2018
Table 42 Market for Breast Cancer, By Region, 2017–2025 (USD Million)
Table 43 Market for Other Cancers, By Region, 2017–2025 (USD Million)
Table 44 Market, By End User, 2017–2025 (USD Million)
Table 45 Market for Hospitals & Outpatient Facilities, By Region, 2017–2025 (USD Million)
Table 46 Market for Independent Radiotherapy Centers, By Region, 2017–2025 (USD Million)
Table 47 Market for Cancer Research Centers, By Region, 2017–2025 (USD Million)
Table 48 Market, By Region, 2017–2025 (USD Million)
Table 49 North America: Market, By Country, 2017–2025 (USD Million)
Table 50 North America: Market, By Product, 2017–2025 (USD Million)
Table 51 North America: Metal-Based Market, By Type, 2017–2025 (USD Million)
Table 52 North America: Market, By Modality, 2017–2025 (USD Million)
Table 53 North America: Market, By Cancer Type, 2017–2025 (USD Million)
Table 54 North America: Market, By End User, 2017–2025 (USD Million)
Table 55 National Average Medicare Reimbursement: Outpatient Prospective Payment System (Opps) Estimated Per Course
Table 56 NCI Funding, By Research Area, 2015–2017 (USD Million)
Table 57 US: Market, By Product, 2017–2025 (USD Million)
Table 58 US: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 59 Canada: Market, By Product, 2017–2025 (USD Million)
Table 60 Canada: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 61 Europe: Market, By Country, 2017–2025 (USD Million)
Table 62 Europe: Market, By Product, 2017–2025 (USD Million)
Table 63 Europe: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 64 Europe: Market, By Modality, 2017–2025 (USD Million)
Table 65 Europe: Market, By Cancer Type, 2017–2025 (USD Million)
Table 66 Europe: Market, By End User, 2017–2025 (USD Million)
Table 67 Germany: Market, By Product, 2017–2025 (USD Million)
Table 68 Germany: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 69 UK: Market, By Product, 2017–2025 (USD Million)
Table 70 UK: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 71 France: Market, By Product, 2017–2025 (USD Million)
Table 72 France: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 73 Spain: Market, By Product, 2017–2025 (USD Million)
Table 74 Spain: Market, By Type, 2017–2025 (USD Million)
Table 75 Italy: Market, By Product, 2017–2025 (USD Million)
Table 76 Italy: Market, By Type, 2017–2025 (USD Million)
Table 77 RoE: Market, By Product, 2017–2025 (USD Million)
Table 78 RoE: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 79 Asia Pacific: Market, By Country, 2017–2025 (USD Million)
Table 80 Asia Pacific: Market, By Product, 2017–2025 (USD Million)
Table 81 Asia Pacific: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 82 Asia Pacific: Market, By Modality, 2017–2025 (USD Million)
Table 83 Asia Pacific: Market, By Cancer Type, 2017–2025 (USD Million)
Table 84 Asia Pacific: Market, By End User, 2017–2025 (USD Million)
Table 85 Japan: Market, By Product, 2017–2025 (USD Million)
Table 86 Japan: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 87 China: Market, By Product, 2017–2025 (USD Million)
Table 88 China: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 89 India: Market, By Product, 2017–2025 (USD Million)
Table 90 India: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 91 South Korea: Market, By Product, 2017–2025 (USD Million)
Table 92 South Korea: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 93 Australia: Market, By Product, 2017–2025 (USD Million)
Table 94 Australia: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 95 RoAPAC: Market, By Product, 2017–2025 (USD Million)
Table 96 RoAPAC: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 97 Latin America: Market, By Country, 2017–2025 (USD Million)
Table 98 Latin America: Market, By Product, 2017–2025 (USD Million)
Table 99 Latin America: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 100 Latin America: Market, By Modality, 2017–2025 (USD Million)
Table 101 Latin America: Market, By Cancer Type, 2017–2025 (USD Million)
Table 102 Latin America: Market, By End User, 2017–2025 (USD Million)
Table 103 Brazil: Market, By Product, 2017–2025 (USD Million)
Table 104 Brazil: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 105 Mexico: Market, By Product, 2017–2025 (USD Million)
Table 106 Mexico: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 107 RoLA: Market, By Product, 2017–2025 (USD Million)
Table 108 RoLA: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 109 MEA: Market, By Product, 2017–2025 (USD Million)
Table 110 MEA: Metal-Based Fiducial Markers Market, By Type, 2017–2025 (USD Million)
Table 111 MEA: Market, By Modality, 2017–2025 (USD Million)
Table 112 MEA: Market, By Cancer Type, 2017–2025 (USD Million)
Table 113 MEA: Market, By End User, 2017–2025 (USD Million)

List of Figures (28 Figures)

Figure 1 Market: Research Methodology Steps
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Research Methodology: Hypothesis Building
Figure 5 Market: Product-Based Estimation
Figure 6 Market: End User-Based Estimation
Figure 7 Market: Data Triangulation
Figure 8 Market Share, By Product, 2019 Vs. 2025
Figure 9 Market Share, By Modality, 2019 Vs. 2025
Figure 10 Market, By Cancer Type, 2019–2025 (USD Million)
Figure 11 Market, By End User, 2019–2025 (USD Million)
Figure 12 Market, By Region: Geographical Snapshot
Figure 13 Growing Adoption of Image-Guided Radiotherapy Across the Globe is Supporting the Growth of the Market
Figure 14 Metal-Based Markers Command the Largest Market Share
Figure 15 CT/CBCT Segment Dominates the Global Market During the Forecast Period
Figure 16 Prostate Cancer Segment Will Hold the Major Share of the Market During the Forecast Period
Figure 17 Hospitals & Outpatient Facilities Segment Command the Largest Market Share
Figure 18 China to Register the Highest CAGR During the Forecast Period
Figure 19 Market: Drivers, Restraints, Opportunities, and Challenges
Figure 20 Number of New Cancer Cases Diagnosed, By Country, 2018 (Thousand)
Figure 21 North America: Market Snapshot
Figure 22 Key Growth Strategies Adopted By Market Players From 2016 to 2019
Figure 23 CIVCO Radiotherapy Held the Leading Position in the Market, 2018
Figure 24 Market (Global) Competitive Leadership Mapping, 2019
Figure 25 Boston Scientific Corporation: Company Snapshot
Figure 26 IBA: Company Snapshot
Figure 27 Medtronic: Company Snapshot
Figure 28 Eckert & Ziegler: Company Snapshot



★調査レポート[フィデューシャルマーカーの世界市場予測:製品別(金属ベースマーカー(金、金の組み合わせ)、ポリマーマーカー)、がん種類別(前立腺、肺、乳房)、モダリティ別(CT、CBCT、MRI、超音波)、エンドユーザー別(病院、外来施設)] ( Fiducial Markers Market by Product (Metal Based Markers (Gold, Gold Combination) Polymer Markers), Cancer Type (Prostate, Lung, Breast), Modality (CT, CBCT, MRI, Ultrasound), End user (Hospitals, Outpatient Facilities) - Global Forecast to 2025 / MD 7554) 販売に関する免責事項
[フィデューシャルマーカーの世界市場予測:製品別(金属ベースマーカー(金、金の組み合わせ)、ポリマーマーカー)、がん種類別(前立腺、肺、乳房)、モダリティ別(CT、CBCT、MRI、超音波)、エンドユーザー別(病院、外来施設)] ( Fiducial Markers Market by Product (Metal Based Markers (Gold, Gold Combination) Polymer Markers), Cancer Type (Prostate, Lung, Breast), Modality (CT, CBCT, MRI, Ultrasound), End user (Hospitals, Outpatient Facilities) - Global Forecast to 2025 / MD 7554) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆